Tomi Jun, MD, Stanford University School of Medicine, discusses results of a multi-center study investigating patients with cyptogenic hepatocellular carcinoma (HCC).

It was confirmed in a large cohort of 4000 patients with cyptogenic HCC, that one-third did not have cirrhosis, explains Jun. It was also discovered that this population presents with a later stage of disease and often with more advanced tumors.

According to Jun, this suggests that if there was better early detection, these patients might have better survival rates.

Videos

Dr. Jun on the Results of a Study Investigating Cyptogenic Hepatocellular Carcinoma

Tomi Jun, MD, Stanford University School of Medicine, discusses cryptogenic hepatocellular carcinoma (HCC).

Although viral liver diseases are seen as the predominant risk factor of HCC, Jun says, there is a population of patients with cryptogenic HCC—mostly those with non-alcoholic fatty liver disease.

Although patients with cryptogenic HCC show less cirrhosis than HCC caused by viral diseases such as hepatitis B and C, the rate of long-term survival is worse.

Tomi Jun, MD, Stanford University School of Medicine, discusses cryptogenic hepatocellular carcinoma.

Dr. Jun Discusses Cyptogenic Hepatocellular Carcinoma

Tomi Jun, MD, Stanford University School of Medicine, discusses the results of a study of cirrhosis and long-term survival in patients with cryptogenic hepatocellular carcinoma (HCC).

This was a multi-center, international cohort of about 4000 patients out of the United States and Taiwan that aimed to evaluate the significantly lower rates of cirrhosis and worse long-term survival in patients with cryptogenic HCC compared with viral etiologies.

Although patients with cryptogenic HCC showed less cirrhosis, survival was significantly lower than what was shown in patients with hepatitis b- and hepatitis c-related HCC.

View more from the 2017 International Liver Congress

Tomi Jun, MD, Stanford University School of Medicine, discusses the results of a study of cirrhosis and long-term survival in patients with cryptogenic hepatocellular carcinoma. 

Tomi Jun, MD

Articles

Dr. Jun on the Results of a Study Investigating Cyptogenic Hepatocellular Carcinoma

Dr. Jun Discusses Cyptogenic Hepatocellular Carcinoma

Dr. Jun on Results of Study in Cryptogenic Hepatocellular Carcinoma